Vasopressin in 0.9% Sodium Chloride Injection
When the Pressure to Treat Hypotension Rises.
Explore this Product
Overview
Indications and Select Important Risk Information
- Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
- Contraindications: Vasopressin in Sodium Chloride Injection is contraindicated in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin.
Please read the accompanying full Indications and Important Risk Information and full Prescribing Information
Vasopressin in 0.9% Sodium Chloride Injection
Premix vasopressin in sodium chloride is available in two strengths to adapt to your facility’s needs.
20 units/100 mL
40 units/100 mL
ISMP and ASHP guidelines recommend using commercially prepared, premixed IV products as a risk-reduction strategy for IV medications.2,3
Vasopressin Benefits
Safety
- Using premix bags with standardized concentration may decrease the likelihood of compounding errors that may be heightened in urgent situations.2,3
- Bags are barcoded for bedside scanning to help ensure the right patient gets the right medication.3
- The distinctly labeled bag differentiates product strength.
Efficiency
- No admixing or batching is required, which may help streamline deployment and save pharmacy time and resources.
- Premix medications like vasopressin support inventory management and help reduce waste.4
Consistent Concentration
A manufacturer-prepared Vasopressin premix helps ensure that patients receive a consistent concentration of medication.3
Features
Storage Options for Your Healthcare Facility Needs
Product must be stored in a light-protective carton during storage.
Delivered in a Flexible GALAXY IV Container
24 Months of Shelf Life when Refrigerated
Six Months of Stability at Room Temperature
The GALAXY container is free of latex, PVC and DEHP.1
Flexibility
The lightweight, flexible GALAXY container is shatterproof and can be transported from the pharmacy to the point of care without the risk of broken glass.
Sterility
The sterile, closed-system GALAXY container is collapsible, delivering the full labeled volume of drug solution and does not require a vented IV set.1 Premixed medications in GALAXY container prevent the need for manual admixtures and offer a closed system, reducing the possibility of contamination.5
Efficiency
Vasopressin is ready for IV administration directly from the GALAXY container. It requires no compounding or transfer to a different container.
Order & Support
Learn More About Vasopressin in 0.9% Sodium Chloride Injection
Ordering and Support Information for Vasopressin in 0.9% Sodium Chloride Injection
Get additional ordering, customer, technical, and medical support information for Vasopressin in 0.9% Sodium Chloride Injection by contacting Baxter using the links below.
U.S. Catalog
To buy this product or look for options and specs please visit U.S. Catalog.
U.S. Support
For manuals and documentation, product training, technical support and services, submit repair and return requests or check order status for Hillrom, Allen Medical and Welch Allyn product please visit U.S. Support.
U.S. Edu
For medical information or non-promotional education about our products or therapies, please visit U.S. Edu.
Plan Your Inventory
View our supply availability report on our Baxter Supply Resources page by clicking the link below.
Contact Us
To find contact details and assistance for Baxter products, report an adverse event or report a product complaint, or any other inquiries, please visit our contact us page.
Resources
More Products
Explore More Products
Other Information
Vasopressin in 0.9% Sodium Chloride Injection
Indication and Important Risk Information
Indication
Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Important Risk Information
- Contraindications: Vasopressin in Sodium Chloride Injection is contraindicated in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin.
- Worsening Cardiac Function: A decrease in cardiac index may be observed with the use of vasopressin.
- Reversible Diabetes Insipidus: Patients may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin. Monitor serum electrolytes, fluid status, and urine output after vasopressin discontinuation. Some patients may require readministration of vasopressin or administration of desmopressin to correct fluid and electrolyte shifts.
Adverse Reactions:
– The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia, and ischemia (coronary, mesenteric, skin, digital).
Drug Interactions:
– Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive.
– Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection.
– Co-administration of ganglionic blockers or drugs causing SIADH (syndrome of inappropriate antidiuretic hormone secretion) may increase the pressor response.
– Co-administration of drugs causing diabetes insipidus may decrease the pressor response.
- Pregnancy: May induce tonic uterine contractions that could threaten the continuation of pregnancy.
Please click for accompanying full Prescribing Information for Vasopressin in 0.9% Sodium Chloride Injection.
Disclaimers
Baxter and Galaxy are trademarks of Baxter International Inc. or its subsidiaries. Any other trademarks, product names or brand images are the property of their respective owners.
References
- Baxter Data on File.
- Institute for Safe Medication Practices. ISMP Guidelines for Sterile Compounding and the Safe Use of Sterile Compounding Technology; 2022. https://www.ismp.org/resources/guidelines-sterile-compounding-and-safe-use-sterile-compounding-technology. Accessed July 8, 2022.
- Billstein-Leber M, Carrillo CJD, Cassano AT, Moline K, Robertson JJ. ASHP Guidelines on Preventing Medication Errors in Hospitals. Am J Health-Syst Pharm. 2018 Oct;75(19):1493-1517. doi 10.2146/ajhp170811
- ASHP Expert Panel on Medication Cost Management. ASHP guidelines on medication cost management strategies for hospitals and health systems. Am J Health-Syst Pharm. 2008;65(14):1368-1384.
- Mercaldi CJ, Lanes S, Bradt J. Comparative risk of bloodstream infection in hospitalized patients receiving intravenous medication by open, point-of-care, or closed delivery systems. Am J Health-Syst Pharm. 2013;70:957-965.